GTC Biotherapeutics, a rare disease company focused on developing and delivering next-generation therapeutics, has changed its name to rEVO Biologics.
The name change reflects the recent commercial growth of the company, and aligns with the company's business strategy of evolving recombinant medicine for the treatment of rare diseases.
"Our company is taking a revolutionary approach to the development of recombinant therapies, as evidenced by our lead product ATryn Antithrombin (Recombinant) and its remarkable growth over the past year," stated rEVO Biologics president Yann Echelard, Ph.D.
"With this change, our name now reflects that core strength. Our rPRO Technology enables us to maintain all of the advantages that recombinant science offers, but through an entirely different approach. The result is better efficiency, better scalability, better cost control and ultimately better patient access to these innovative therapies."
ATryn Antithrombin (Recombinant) is the first and only recombinant antithrombin concentrate, and is currently the growing antithrombin product with market share that has tripled in the last 12 months.